UCB’s Cimzia Rejected For Crohn’s By EMEA Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.
You may also be interested in...
UCB’s Cimzia Shows Strong Interim Results In Phase IIIb For Crohn’s Disease
New data bolsters firm’s appeal of a negative opinion from EU authorities.
UCB’s Cimzia Shows Strong Interim Results In Phase IIIb For Crohn’s Disease
New data bolsters firm’s appeal of a negative opinion from EU authorities.
UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis
The biologic, which has yet to obtain a Crohn’s indication in the U.S. and Europe, is backed by efficacy data from three Phase III trials in RA.